Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228949 | 0.91 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL5015592 | 0.89 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2889102 | 0.89 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2883240 | 0.89 | ADORA2A (0.60) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4218934 | 0.86 | ADORA2A (0.68) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2883248 | 0.84 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1836349 | 0.83 | ADORA2A (0.68) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL238656 | 0.83 | ADORA2A (0.68) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL238564 | 0.81 | ADORA2A (0.60) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL243059 | 0.81 | ADORA2A (0.67) | ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.